Atorvastatin
The mean ± SD of Cmax and AUC0-t of oral atorvastatin before repeated administration of carotegrast methyl (day -1) was 3.2 ± 1.5 ng mL-1 and 16.1 ± 6.2 ng h mL-1, respectively. The Cmax and AUC0-t of atorvastatin after 14 days administration of carotegrast methyl administration (day 14) was 4.0 ± 2.4 ng mL-1 and 33.8 ± 13.8 ng h mL-1, respectively. The geometric mean ratio of the Cmax and AUC0-t of atorvastatin on day 14 to those on day -1 was 1.24 (90% CI, 1.01 – 1.52) and 2.10 (90% CI, 1.97 – 2.24), which did not fall within the range of 0.80 – 1.25, suggesting that carotegrast methyl had a pharmacokinetic interaction with oral atorvastatin. The Cmax and AUC0-t of atorvastatin 14 days after the end of carotegrast methyl administration (day 28) was 3.3 ± 1.4 ng mL-1 and 17.9 ± 6.8 ng h mL-1, respectively. The geometric mean ratio of the Cmax and AUC0-t of atorvastatin on day 28 to those on day -1 was 1.06 (90% CI, 0.87 – 1.30) and 1.13 (90% CI, 1.06 – 1.20), respectively, which fell within the range of 0.80 − 1.25.
The Tmax of atorvastatin and prednisolone with coadministration of carotegrast methyl was delayed compared with the Tmax without carotegrast methyl coadministration. No change in Tmax was observed when carotegrast methyl was combined with oral midazolam.